Oncorus, Inc., an RNA medicines company focused on developing intravenously administered, self-amplifying RNA to transform outcomes for cancer patients, has approved a workforce reduction of approximately 55 employees, virtually all of its workforce, by August 2023. The company’s board of directors approved the move in response to challenges associated with raising additional capital and pursuing strategic alternatives to secure additional funding, including current market conditions. Theo...